Lv1
30 积分 2025-06-16 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1天前
待确认
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
12天前
已完结
Navigating the complexities of drug development for inflammatory bowel disease
13天前
已完结
Worldwide prevalence of prurigo nodularis: A systematic review and meta‐analysis
17天前
已完结
Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus
17天前
已完结
Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression
18天前
已完结
Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)
2个月前
已关闭
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
3个月前
已完结
JAK inhibitors in 2019, synthetic review in 10 points
3个月前
已完结
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
4个月前
已完结
皖公网安备34019202002308
